Celiac disease is a genetic autoimmune disorder that affects approximately 1% of the global population. In celiac disease, ingestion of gluten leads to damage of the villi in the small intestine. This can lead to long-term health conditions such as vitamin and mineral deficiencies and early onset of osteoporosis or osteopenia. Furthermore, it can lead to more malignant conditions such as Non-Hodgkin lymphoma and small intestinal adenocarcinoma.

There is no approved drug for the treatment of Celiac disease. No medication exists that can prevent the immune attack or repair the damage to the villi resulting from exposure to gluten. Therefore, current treatment is limited to maintaining a gluten-free diet. Failure to comply with a gluten-free diet, especially when inadvertent at a restaurant or cafeteria, will typically lead to relapse as the underlying pathology of celiac disease remains unaddressed.

TIMP-GLIA seeks to prevent these long-term and severe conditions by tolerizing the body to gluten. Using Cour’s novel technology for TIMP-GLIA, the body is reprogrammed to recognize gluten as a non-threatening substance and subsequently abrogates/reverses the signs and symptoms of Celiac disease.

TIMP-GLIA is currently in clinical trials. To learn more, visit clinicaltrials.gov.



Food and Environmental allergies are Immunoglobulin E-mediated (IgE) responses to food and environmental allergens. Symptoms can range from allergic rhinitis to life-threatening anaphylaxis. Typical treatment of allergies involves avoidance of the allergen or management of the symptoms with medications such as anti-histamines. Furthermore, current immunotherapy treatments provide limited protection and/or only prevent accidental exposure to the allergen (i.e. accidentally consuming a peanut butter cookie).

Eight types of food account for about 90% of all food-related allergic reactions. These foods are: Eggs, Milk, Peanuts, Tree Nuts, Fish, Shellfish, Wheat, and Soy. Environment allergens can be plant, animal, or insect based. Common environmental allergens include pollen, cats, dogs, and dust mites. Cour is specifically developing therapeutics modeled from our TIMP platform technology to treat the wide array of food and environmental allergies.



Cour’s novel TIMP platform has the potential to treat many other autoimmune diseases beside celiac disease. We are optimizing our product as a therapy for several of these diseases.



Monoclonal antibodies have been developed to treat a variety of diseases ranging from Rheumatoid Arthritis to Cancer. Unfortunately, patients can develop anti-drug antibodies which can cause severe allergic reactions or reduce the efficacy of the monoclonal antibody.

Cour is using it’s novel TIMP platform to improve the effectiveness of current monoclonal antibody therapies.




Acute Myocardial Infarction, better known as a heart attack, affects 1.5 million people each year and approximately one-third die in the acute phase of the attack. A key feature of acute myocardial infarction is it’s associated excessive inflammation that can lead to ischemia (cell death) in the heart.

Cour’s novel IMP technology mitigates the excessive inflammation in a heart attack and intends to improve the chance of survival.



Tropical & infectious diseases may cause excessive inflammation leading to death. In the case of malaria, severe cerebral inflammation in response to exposure to the parasite can lead to death.

Cour’s novel IMP technology mitigates the excessive cerebral inflammation and intends to improve the chance of survival.